Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255155 | 0.94 | CTSV (0.33) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8246214 | 0.92 | CTSB (0.34) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8250408 | 0.92 | — | — | |
| SCHEMBL13225003 | 0.91 | CTSB (0.38) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8243397 | 0.91 | CTSB (0.33) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8250153 | 0.91 | ELANE (0.40) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8248098 | 0.91 | — | — | |
| SCHEMBL8250416 | 0.90 | CTSV (0.32) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8250454 | 0.89 | ELANE (0.43) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL13251633 | 0.89 | CTSV (0.42) | CTSVCTSLCTSBELANECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-7772178-B2 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772178-B2 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7342041-B2 | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342041-B2 | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| WO-2006130686-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130553-A2 | HCV PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130628-A2 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130627-A2 | METHODS FOR TREATING HEPATITIS C | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006113942-A2 | METHOD OF INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | CTSV 32/4885CTSL 65/4885CTSB 193/4885 |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | CTSV 33/4885CTSL 109/4885CTSB 199/4885 |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | LPXN, SLC5A11, F12 | CTSV 1420/4885CTSL 3343/4885CTSB 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.